

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Xanomeline tartrate–trospium chloride for treating schizophrenia ID6716

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Bristol Myers Squibb (xanomeline tartrate–trospium chloride) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Hearing Voices Network • Living With Schizophrenia UK • Making Space • Mental Health Foundation • Mental Health Matters • Mental Health UK • Mind • Race Equality Foundation • Rethink Mental Illness • SANE • South Asian Health Foundation • Specialised Healthcare Alliance • Together <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • British Association for Counselling and Psychotherapy • British Association of Behavioural and Cognitive Psychotherapies • British Association of Occupational Therapists and College of Occupational Therapists • British Association of Psychopharmacology • British Association of Social Workers • British Geriatrics Society • British Neuropsychiatry Association • British Psychoanalytic Council • British Psychological Society • College of Mental Health Pharmacy • Counsellors and Psychotherapists in Primary Care 	<p><u>General</u></p> <ul style="list-style-type: none"> • Adferiad Recovery • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Council for Wales • Care Quality Commission • Change Mental Health • Department of Health - Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • MIND Cymru • National Association of Primary Care • National Pharmacy Association • NHS Confederation • NHS Wales Joint Commissioning Committee • Scottish Association for Mental Health • Scottish Medicines Consortium • Social Care Institute for Excellence • Welsh Government <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • ADVANZ Pharma (amisulpride, haloperidol, paliperidone) • AmaroX (aripiprazole) • Aspire Pharma (aripiprazole, lurasidone hydrochloride) • Aurobindo Pharma (aripiprazole, amisulpride, olanzapine, risperidone) • Britannia pharmaceuticals (clozapine) • CNX Therapeutics (lurasidone hydrochloride)

Provisional stakeholder list for the evaluation of xanomeline tartrate–trospium chloride for treating schizophrenia ID6716

Issue date: May 2026

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Health and Care Professionals Council • Mental Health Nurses Association • Primary Care Mental Health Education • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Psychiatrists • Royal Pharmaceutical Society • Royal Society of Medicine • The Black, African and Asian Therapy Network • UK Clinical Pharmacy Association • UK Council for Psychotherapy <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<ul style="list-style-type: none"> • Dexcel Pharma (lurasidone hydrochloride, risperidone) • Dr. Reddy's Laboratories (olanzapine, chlorpromazine hydrochloride) • Eramol (olanzapine) • Essential Pharma (haloperidol, haloperidol decanoate) • Galvany Pharma (haloperidol) • Genus Pharmaceuticals (paliperidone) • Glenmark Pharmaceuticals (olanzapine, risperidone) • Grindeks Kalceks (risperidone) • Janssen-Cilag (risperidone, paliperidone) • Krka UK (aripiprazole, olanzapine, risperidone) • Leyden Delta (clozapine) • Neon Healthcare (aripiprazole, olanzapine) • Novumgen (aripiprazole) • Otsuka pharmaceuticals (aripiprazole) • Pinewood (haloperidol, chlorpromazine hydrochloride) • Ranbaxy (olanzapine, risperidone) • Rosemont Pharmaceuticals (risperidone, chlorpromazine hydrochloride) • ROVI Biotech (risperidone) • RPH Pharmaceuticals (haloperidol) • Sandoz (aripiprazole, olanzapine, risperidone) • SyriMed (aripiprazole, amisulpride, haloperidol) • Thornton & Ross (aripiprazole) • Unicorn Pharmaceuticals (aripiprazole) • Viatrix (aripiprazole, amisulpride, risperidone, clozapine) • Wockhardt UK (haloperidol) • Zentiva (aripiprazole, risperidone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Campbell Collaboration Social Welfare Group • Careif • Cochrane Schizophrenia Group

Provisional stakeholder list for the evaluation of xanomeline tartrate–trospium chloride for treating schizophrenia ID6716
Issue date: May 2026

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • Genomics England • Health Services Research Unit • Institute of Psychiatry • Joseph Rowntree Foundation • MQ Mental Health Research • MRC Clinical Trials Unit • National Institute for Health Research • National Primary Care Research & Development Centre • Schizophrenia Research Fund • Wellcome Trust <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.